Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syndax Pharmaceuticals, Inc. (SNDX)
USD22.89
-0.72 (-3.05%)
US NASDAQ Healthcare Biotechnology
Address
35 Gatehouse Drive 2451
New York City, MA, US
New York City, MA, US
CEO
Michael A. Metzger
Website
syndax.com
IPO
2016-03-02
CIK 1395937 ISIN US87164F1057
Description
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD22.89
-0.72 (-3.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.37
Float Shares
75.04M
Free Float %
85.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.54% | -0.63% | -15.84% | -0.34% | +22.51% | -2.86% | +100.29% | -3.50% | +12.70% | +60.08% | +70.08% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
22.89
Low
37.00
+61.6%
Consensus
41.50
+81.3%
Median
41.50
+81.3%
High
46.00
+101.0%
DCF (Unlevered)
15.08
-34.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
41.50
+81.3%
|
| Last Quarter | 3 |
42.67
+86.4%
|
| Last Year | 9 |
35.56
+55.4%
|
| All Time | 20 |
34.65
+51.4%
|
Quality scores
Altman Z-Score
-1.58
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+627.8% ★ Q1'26: +223.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+11.8% Q1'26: +50.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-211.6% Q1'26: -77.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-146.0% Q1'26: -47.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,476.5% Q1'26: -353.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.2% ★ Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.38× Q1'26: -2.80× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 11 Rev. Ana. 9 EPS Ana. |
Dec 2029 5 Rev. Ana. 3 EPS Ana. |
Dec 2030 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.22M
est: 1.16M (+5.3%)
|
2.11M
est: 1.23M (+71.0%)
|
1.52M
est: 1.60M (-5.0%)
|
1.52M
est: 1.50M (+1.3%)
|
1.52M
est: 1.47M (+3.5%)
|
139.71M
est: 19.15M (+629.6%)
|
—
est: 375.0K (-100.0%)
|
—
est: 3.50M (-100.0%)
|
23.68M
est: 48.27M (-50.9%)
|
172.35M
est: 168.15M (+2.5%)
|
348.00M
325.83M – 369.70M
+107.0% YoY
|
513.73M
463.06M – 610.75M
+47.6% YoY
|
699.40M
681.65M – 717.15M
+36.1% YoY
|
912.23M
775.89M – 1.18B
+30.4% YoY
|
1.12B
952.95M – 1.45B
+22.8% YoY
|
| EBITDA |
-43.68M
est: 44.6K (-98,078.8%)
|
-61.88M
est: 47.4K (-130,641.5%)
|
-73.88M
est: 61.4K (-120,403.2%)
|
-55.60M
est: 57.6K (-96,614.1%)
|
-70.29M
est: 56.4K (-124,822.3%)
|
26.87M
est: 736.6K (+3,547.8%)
|
-146.17M
est: 14.4K (-1,013,536.9%)
|
-209.14M
est: 134.6K (-155,457.0%)
|
-313.82M
est: 1.86M (-17,001.9%)
|
-251.63M
est: 6.47M (-3,990.8%)
|
13.39M
12.53M – 14.22M
+107.0% YoY
|
19.76M
17.81M – 23.49M
+47.6% YoY
|
26.90M
26.22M – 27.58M
+36.1% YoY
|
35.09M
29.84M – 45.29M
+30.4% YoY
|
43.09M
36.65M – 55.62M
+22.8% YoY
|
| EBIT |
-43.77M
est: 44.5K (-98,435.1%)
|
-61.95M
est: 47.3K (-131,011.8%)
|
-73.96M
est: 61.3K (-120,724.6%)
|
-56.05M
est: 57.5K (-97,552.7%)
|
-70.80M
est: 56.3K (-125,937.1%)
|
26.83M
est: 735.4K (+3,547.8%)
|
-146.20M
est: 14.4K (-1,015,384.7%)
|
-209.15M
est: 134.4K (-155,714.4%)
|
-313.83M
est: 1.85M (-17,029.5%)
|
-251.64M
est: 6.46M (-3,997.1%)
|
13.36M
12.51M – 14.20M
+107.0% YoY
|
19.73M
17.78M – 23.45M
+47.6% YoY
|
26.86M
26.18M – 27.54M
+36.1% YoY
|
35.03M
29.80M – 45.21M
+30.4% YoY
|
43.02M
36.59M – 55.53M
+22.8% YoY
|
| Net Income |
-44.47M
est: -305.63M (+85.4%)
|
-60.80M
est: -242.47M (+74.9%)
|
-73.96M
est: -251.70M (+70.6%)
|
-55.96M
est: -156.22M (+64.2%)
|
-73.07M
est: -159.57M (+54.2%)
|
24.93M
est: -174.82M (+114.3%)
|
-149.34M
est: -216.75M (+31.1%)
|
-209.36M
est: -264.08M (+20.7%)
|
-318.76M
est: -280.91M (-13.5%)
|
-285.42M
est: -268.76M (-6.2%)
|
-143.54M
-241.03M – -108.37M
+46.6% YoY
|
13.71M
-136.28M – 44.73M
+109.6% YoY
|
67.56M
49.85M – 85.26M
+392.8% YoY
|
183.82M
148.10M – 253.29M
+172.1% YoY
|
267.15M
215.25M – 368.12M
+45.3% YoY
|
| SGA |
13.32M
est: 5.13M (+159.8%)
|
15.86M
est: 5.45M (+190.9%)
|
17.29M
est: 7.06M (+144.7%)
|
16.06M
est: 6.63M (+142.4%)
|
22.51M
est: 6.48M (+247.2%)
|
25.24M
est: 84.72M (-70.2%)
|
33.26M
est: 1.66M (+1,904.7%)
|
66.92M
est: 5.83M (+1,048.0%)
|
120.88M
est: 80.40M (+50.3%)
|
179.68M
est: 280.06M (-35.8%)
|
579.62M
542.69M – 615.76M
+107.0% YoY
|
855.65M
771.26M – 1.02B
+47.6% YoY
|
1.16B
1.14B – 1.19B
+36.1% YoY
|
1.52B
1.29B – 1.96B
+30.4% YoY
|
1.87B
1.59B – 2.41B
+22.8% YoY
|
| EPS |
-3.04
est: -3.57 (+14.8%)
|
-2.90
est: -2.83 (-2.4%)
|
-2.92
est: -2.94 (+0.7%)
|
-1.84
est: -1.82 (-0.8%)
|
-1.77
est: -1.86 (+5.0%)
|
0.48
est: -2.04 (+123.5%)
|
-2.46
est: -2.53 (+2.8%)
|
-2.98
est: -3.38 (+11.7%)
|
-3.73
est: -3.48 (-7.3%)
|
-3.29
est: -3.10 (-6.0%)
|
-1.80
-2.78 – -1.25
+42.0% YoY
|
-0.55
-1.57 – 0.52
+69.3% YoY
|
0.71
0.58 – 0.98
+229.3% YoY
|
2.12
1.71 – 2.92
+197.1% YoY
|
3.08
2.48 – 4.25
+45.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-01 | Barclays | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-273.82M
OE per share TTM
-3.17
Owner's Yield
-14.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
38
Total invested
20.27M
Insider transactions (90d)
0
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Group Holdings LLP | 7.98M | 11.72% | — | 7.22M | — | — | HC | Massachusetts | 2023-01-10 | ↗ |
| 2 | Wellington Investment Advisors Holdings LLP | 7.98M | 11.72% | — | 7.22M | — | — | HC | Massachusetts | 2023-01-10 | ↗ |
| 3 | Wellington Management Group LLP | 7.98M | 11.72% | — | 7.22M | — | — | HC | Massachusetts | 2023-01-10 | ↗ |
| 4 | Wellington Management Company LLP | 7.63M | 11.21% | — | 7.19M | — | — | IA | Massachusetts | 2023-01-10 | ↗ |
| 5 | Kynam Capital Management GP, LLC | 5.66M | 6.67% | — | 5.66M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 6 | Kynam Capital Management, LP | 5.66M | 6.67% | — | 5.66M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 7 | Yue Tang | 5.66M | 6.67% | — | 5.66M | — | — | IN | Delaware | 2024-02-14 | ↗ |
| 8 | Avidity Capital Partners (GP) LLC | 5.24M | 9.90% | — | 5.24M | — | 5.24M | OO | — | 2022-02-14 | ↗ |
| 9 | Avidity Capital Partners Fund (GP) LP | 5.24M | 9.90% | — | 5.24M | — | 5.24M | PN, OO | — | 2022-02-14 | ↗ |
| 10 | Avidity Partners Management (GP) LLC | 5.24M | 9.90% | — | 5.24M | — | 5.24M | OO | — | 2022-02-14 | ↗ |
| 11 | Avidity Partners Management LP | 5.24M | 9.90% | — | 5.24M | — | 5.24M | IA, PN | — | 2022-02-14 | ↗ |
| 12 | David Witzke | 5.24M | 9.90% | — | 5.24M | — | 5.24M | IN | — | 2022-02-14 | ↗ |
| 13 | Michael Gregory | 5.24M | 9.90% | — | 5.24M | — | 5.24M | IN | — | 2022-02-14 | ↗ |
| 14 | Avidity Master Fund LP | 4.51M | 8.50% | — | 4.51M | — | 4.51M | PN, OO | — | 2022-02-14 | ↗ |
| 15 | The Vanguard Group - 23-1945930 | 4.34M | 5.11% | — | — | 4.16M | 178.4K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 16 | 2 | 3.52M | 5.10% | — | — | — | 3.52M | IN | Delaware | 2023-10-31 | ↗ |
| 17 | Daniel Mack | 3.05M | 5.80% | — | 3.05M | — | — | HC | USA | 2022-02-14 | ↗ |
| 18 | Nantahala Capital Management, LLC | 3.05M | 5.80% | — | 3.05M | — | — | IA | USA | 2022-02-14 | ↗ |
| 19 | Wilmot B. Harkey | 3.05M | 5.80% | — | 3.05M | — | — | HC | MA | 2022-02-14 | ↗ |
| 20 | AI Life Sciences Investments LLC | 2.60M | 4.70% | 2.60M | — | 2.60M | — | OO | — | 2022-03-04 | ↗ |
| 21 | Access Industries Holdings (BVI) L.P. | 2.60M | 4.70% | — | 2.60M | — | 2.60M | PN | — | 2022-03-04 | ↗ |
| 22 | Access Industries Holdings LLC | 2.60M | 4.70% | — | 2.60M | — | 2.60M | OO | — | 2022-03-04 | ↗ |
| 23 | Access Industries Management, LLC | 2.60M | 4.70% | — | 2.60M | — | 2.60M | OO | — | 2022-03-04 | ↗ |
| 24 | Access Industries, LLC | 2.60M | 4.70% | — | 2.60M | — | 2.60M | OO | — | 2022-03-04 | ↗ |
| 25 | LSI-SPV | 2.60M | 4.70% | — | 2.60M | — | 2.60M | OO | — | 2022-03-04 | ↗ |
| 26 | Len Blavatnik | 2.60M | 4.70% | — | 2.60M | — | 2.60M | IN | — | 2022-03-04 | ↗ |
| 27 | Adage Capital Partners GP, L.L.C. | 1.20M | 2.28% | — | 1.20M | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 28 | Phillip | 1.20M | 2.28% | — | 1.20M | — | — | IN | United States | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
38
-209 vs prev Q
New positions
10
Closed positions
202
Increased
17
Reduced
12
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.86M +1.9M (+100.0%) | 38.97B +39.0B (+100.0%) | 2.14% +2.142 pp | 11.50% +11.502 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 180.0K +180.0K (+100.0%) | 3.78B +3.8B (+100.0%) | 0.21% +0.208 pp | 0.01% +0.006 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 8.24M -386.2K (-4.5%) | 173.10M +40.4M (+30.4%) | 9.51% -0.479 pp | 0.00% +0.001 pp | USD17.01 +23.5% | 6 qtrs — |
| 4 | KYNAM CAPITAL MANAGEMENT, LP | 8.05M -469.0K (-5.5%) | 169.15M +38.1M (+29.0%) | 9.29% -0.574 pp | 10.81% +1.046 pp | USD18.19 +15.5% | 17 qtrs — |
| 5 | VANGUARD GROUP INC | 6.23M +1.1M (+21.2%) | 130.90M +51.8M (+65.6%) | 7.19% +1.241 pp | 0.00% +0.001 pp | USD19.05 +10.3% | 39 qtrs — |
| 6 | GOLDMAN SACHS GROUP INC | 5.70M +208.9K (+3.8%) | 119.66M +35.3M (+41.8%) | 6.58% +0.220 pp | 0.01% +0.004 pp | USD13.20 +59.2% | 33 qtrs — |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 4.88M +627.0K (+14.7%) | 102.57M +37.1M (+56.7%) | 5.64% +0.708 pp | 0.11% +0.005 pp | USD16.45 +27.7% | 13 qtrs — |
| 8 | BANK OF AMERICA CORP /DE/ | 4.71M +1.0M (+27.4%) | 98.97M +42.1M (+74.0%) | 5.44% +1.155 pp | 0.01% +0.003 pp | USD14.11 +48.9% | 39 qtrs — |
| 9 | STATE STREET CORP | 4.60M +743.0K (+19.3%) | 96.57M +37.3M (+62.9%) | 5.31% +0.843 pp | 0.00% +0.001 pp | USD20.18 +4.1% | 39 qtrs — |
| 10 | EVERSEPT PARTNERS, LP | 3.31M -152.9K (-4.4%) | 69.64M +16.3M (+30.5%) | 3.83% -0.190 pp | 3.51% -0.167 pp | USD12.96 +62.1% | 15 qtrs — |
| 11 | FRANKLIN RESOURCES INC | 2.42M +31.1K (+1.3%) | 50.88M +14.1M (+38.3%) | 2.80% +0.027 pp | 0.01% +0.003 pp | USD18.79 +11.8% | 9 qtrs — |
| 12 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.35M -150.0K (-6.0%) | 49.37M +10.9M (+28.4%) | 2.71% -0.183 pp | 5.87% +1.096 pp | USD16.80 +25.1% | 9 qtrs — |
| 13 | HOOD RIVER CAPITAL MANAGEMENT LLC | 2.32M +2.3M (+100.0%) | 48.67M +48.7M (+100.0%) | 2.67% +2.674 pp | 0.53% +0.534 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 14 | SOLEUS CAPITAL MANAGEMENT, L.P. | 2.25M +235.0K (+11.7%) | 47.21M +16.3M (+52.5%) | 2.59% +0.264 pp | 1.74% +0.183 pp | USD15.72 +33.7% | 13 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 2.09M -399.0 (0.0%) | 43.94M +11.8M (+36.5%) | 2.41% -0.008 pp | 0.00% +0.001 pp | USD18.85 +11.5% | 39 qtrs — |
| 16 | ENSIGN PEAK ADVISORS, INC | 1.60M +789.5K (+97.6%) | 33.59M +21.1M (+169.8%) | 1.85% +0.908 pp | 0.06% +0.039 pp | USD18.05 +16.4% | 25 qtrs — |
| 17 | NUVEEN, LLC | 1.48M +7.2K (+0.5%) | 31.16M +8.5M (+37.2%) | 1.71% +0.003 pp | 0.01% +0.002 pp | USD14.78 +42.2% | 4 qtrs — |
| 18 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.38M +139.6K (+11.3%) | 28.90M +9.9M (+52.0%) | 1.59% +0.157 pp | 0.03% -0.016 pp | USD16.31 +28.8% | 6 qtrs — |
| 19 | STEMPOINT CAPITAL LP | 1.34M -26.8K (-2.0%) | 28.14M +7.1M (+33.9%) | 1.55% -0.036 pp | 4.83% +0.614 pp | USD15.19 +38.3% | 9 qtrs — |
| 20 | BIOIMPACT CAPITAL LLC | 1.34M -38.0K (-2.8%) | 28.11M +6.9M (+32.8%) | 1.54% -0.049 pp | 3.22% -0.249 pp | USD15.39 +36.5% | 2 qtrs — |
| 21 | AISLING CAPITAL MANAGEMENT LP | 1.32M +— (+0.0%) | 27.67M +7.4M (+36.5%) | 1.52% -0.005 pp | 5.78% +1.337 pp | USD11.05 +90.1% | 24 qtrs — |
| 22 | WOODLINE PARTNERS LP | 1.25M -299.9K (-19.3%) | 26.28M +2.4M (+10.2%) | 1.44% -0.352 pp | 0.10% -0.011 pp | USD21.16 -0.7% | 11 qtrs — |
| 23 | EVENTIDE ASSET MANAGEMENT, LLC | 1.24M +249.7K (+25.3%) | 26.01M +10.8M (+71.1%) | 1.43% +0.285 pp | 0.41% +0.156 pp | USD16.96 +23.9% | 6 qtrs — |
| 24 | D. E. SHAW & CO., INC. | 1.22M +142.0K (+13.2%) | 25.62M +9.0M (+54.6%) | 1.41% +0.160 pp | 0.01% +0.005 pp | USD15.39 +36.5% | 14 qtrs — |
| 25 | CATALIO CAPITAL MANAGEMENT, LP | 1.20M -417.9K (-25.9%) | 25.14M +302.5K (+1.2%) | 1.38% -0.489 pp | 4.44% -0.148 pp | USD11.78 +78.4% | 4 qtrs — |
| 26 | TWO SIGMA INVESTMENTS, LP | 1.15M +434.3K (+60.9%) | 24.10M +13.1M (+119.8%) | 1.32% +0.499 pp | 0.03% +0.018 pp | USD18.70 +12.4% | 12 qtrs — |
| 27 | BANK OF NEW YORK MELLON CORP | 1.09M +41.8K (+4.0%) | 22.99M +6.8M (+42.0%) | 1.26% +0.044 pp | 0.00% +0.001 pp | USD16.03 +31.1% | 38 qtrs — |
| 28 | MORGAN STANLEY | 1.08M -123.8K (-10.3%) | 22.60M +4.1M (+22.5%) | 1.24% -0.148 pp | 0.00% +0.000 pp | USD14.75 +42.4% | 40 qtrs — |
| 29 | ALGERT GLOBAL LLC | 928.1K -2.7K (-0.3%) | 19.50M +5.2M (+36.2%) | 1.07% -0.007 pp | 0.30% +0.064 pp | USD15.23 +38.0% | 17 qtrs — |
| 30 | AQR CAPITAL MANAGEMENT LLC | 926.0K +367.9K (+65.9%) | 19.45M +10.9M (+126.6%) | 1.07% +0.423 pp | 0.01% +0.005 pp | USD17.02 +23.4% | 16 qtrs — |
| 31 | CANDRIAM S.C.A. | 925.3K +— (+0.0%) | 19.44M +5.2M (+36.6%) | 1.07% -0.004 pp | 0.10% +0.022 pp | USD16.89 +24.4% | 12 qtrs — |
| 32 | PALO ALTO INVESTORS LP | 794.5K +139.6K (+21.3%) | 16.69M +6.6M (+65.7%) | 0.92% +0.159 pp | 2.32% +0.459 pp | USD17.48 +20.2% | 24 qtrs — |
| 33 | SPHERA FUNDS MANAGEMENT LTD. | 762.6K +374.8K (+96.7%) | 16.02M +10.1M (+168.6%) | 0.88% +0.431 pp | 3.10% +1.839 pp | USD18.81 +11.7% | 24 qtrs — |
| 34 | JANE STREET GROUP, LLC | 748.9K +10.7K (+1.4%) | 15.73M +4.4M (+38.5%) | 0.86% +0.010 pp | 0.00% +0.001 pp | USD14.58 +44.1% | 13 qtrs — |
| 35 | NORTHERN TRUST CORP | 728.9K -47.8K (-6.1%) | 15.31M +3.4M (+28.2%) | 0.84% -0.058 pp | 0.00% +0.000 pp | USD16.57 +26.8% | 39 qtrs — |
| 36 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 727.4K +8.4K (+1.2%) | 15.28M +4.2M (+38.2%) | 0.84% +0.007 pp | 0.00% +0.001 pp | USD18.68 +12.5% | 39 qtrs — |
| 37 | APIS CAPITAL ADVISORS, LLC | 724.0K +86.0K (+13.5%) | 15.21M +5.4M (+55.0%) | 0.84% +0.097 pp | 2.65% +0.482 pp | USD16.06 +30.8% | 2 qtrs — |
| 38 | UBS GROUP AG | 716.2K -958.3K (-57.2%) | 15.05M -10.7M (-41.6%) | 0.83% -1.113 pp | 0.00% -0.002 pp | USD13.77 +52.6% | 39 qtrs — |
| 39 | QUBE RESEARCH & TECHNOLOGIES LTD | 688.1K -956.7K (-58.2%) | 14.46M -10.8M (-42.9%) | 0.79% -1.111 pp | 0.01% -0.012 pp | USD14.07 +49.3% | 12 qtrs — |
| 40 | PROSIGHT MANAGEMENT, LP | 665.0K -338.4K (-33.7%) | 13.97M -1.5M (-9.5%) | 0.77% -0.395 pp | 2.89% -0.713 pp | USD15.73 +33.6% | 7 qtrs — |
| 41 | SILVERARC CAPITAL MANAGEMENT, LLC | 642.9K +179.2K (+38.6%) | 13.51M +6.4M (+89.3%) | 0.74% +0.205 pp | 1.88% +0.914 pp | USD17.06 +23.2% | 7 qtrs — |
| 42 | TWO SIGMA ADVISERS, LP | 632.8K +249.7K (+65.2%) | 13.29M +7.4M (+125.6%) | 0.73% +0.287 pp | 0.03% +0.014 pp | USD21.71 -3.2% | 25 qtrs — |
| 43 | PARKMAN HEALTHCARE PARTNERS LLC | 574.0K -272.9K (-32.2%) | 12.06M -969.3K (-7.4%) | 0.66% -0.318 pp | 1.15% -0.211 pp | USD16.80 +25.1% | 11 qtrs — |
| 44 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 554.8K +482.3K (+665.6%) | 11.66M +10.5M (+945.5%) | 0.64% +0.557 pp | 0.09% +0.080 pp | USD20.28 +3.6% | 16 qtrs — |
| 45 | RENAISSANCE TECHNOLOGIES LLC | 544.8K -315.7K (-36.7%) | 11.45M -1.8M (-13.5%) | 0.63% -0.368 pp | 0.02% +0.000 pp | USD12.58 +67.0% | 10 qtrs — |
| 46 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 515.1K +390.6K (+313.5%) | 10.82M +8.9M (+464.9%) | 0.59% +0.450 pp | 0.12% +0.110 pp | USD19.57 +7.4% | 6 qtrs — |
| 47 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 487.0K -87.0K (-15.2%) | 10.23M +1.4M (+15.9%) | 0.56% -0.103 pp | 0.96% -0.021 pp | USD15.82 +32.8% | 8 qtrs — |
| 48 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 434.1K +21.1K (+5.1%) | 9.12M +2.8M (+43.5%) | 0.50% +0.023 pp | 0.00% +0.000 pp | USD15.76 +33.3% | 32 qtrs — |
| 49 | CAPTION MANAGEMENT, LLC | 424.5K -194.3K (-31.4%) | 8.92M -601.5K (-6.3%) | 0.49% -0.227 pp | 0.06% -0.013 pp | USD13.20 +59.2% | 6 qtrs — |
| 50 | KNOTT DAVID M JR | 415.0K -13.0K (-3.0%) | 8.72M +2.1M (+32.4%) | 0.48% -0.017 pp | 4.04% +1.382 pp | USD14.20 +48.0% | 8 qtrs — |
| 51 | JPMORGAN CHASE & CO | 378.5K +124.7K (+49.1%) | 7.95M +4.0M (+103.6%) | 0.44% +0.143 pp | 0.00% +0.000 pp | USD18.28 +14.9% | 39 qtrs — |
| 52 | ABRDN PLC | 372.8K +— (+0.0%) | 7.83M +2.1M (+36.6%) | 0.43% -0.001 pp | 0.01% +0.003 pp | USD11.78 +78.4% | 5 qtrs — |
| 53 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 366.8K -29.5K (-7.5%) | 7.71M +1.6M (+26.4%) | 0.42% -0.036 pp | 0.33% +0.080 pp | USD14.91 +40.9% | 9 qtrs — |
| 54 | BARCLAYS PLC | 314.7K +127.0K (+67.7%) | 6.61M +3.0M (+83.0%) | 0.36% +0.146 pp | 0.00% +0.001 pp | USD16.96 +23.9% | 39 qtrs — |
| 55 | PALE FIRE CAPITAL SE | 284.5K +284.5K (+100.0%) | 5.98M +6.0M (+100.0%) | 0.33% +0.328 pp | 0.40% +0.401 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 56 | AMERIPRISE FINANCIAL INC | 282.6K +187.1K (+196.1%) | 5.94M +4.5M (+304.3%) | 0.33% +0.216 pp | 0.00% +0.001 pp | USD18.20 +15.4% | 11 qtrs — |
| 57 | DAFNA CAPITAL MANAGEMENT LLC | 277.9K -222.8K (-44.5%) | 5.84M -1.9M (-24.2%) | 0.32% -0.259 pp | 1.36% -0.547 pp | USD21.10 -0.4% | 23 qtrs — |
| 58 | SECTOR GAMMA AS | 252.1K +41.2K (+19.6%) | 5.30M +2.1M (+63.3%) | 0.29% +0.047 pp | 1.21% +0.403 pp | USD16.31 +28.8% | 2 qtrs — |
| 59 | PFM HEALTH SCIENCES, LP | 243.0K -13.5K (-5.3%) | 5.10M +1.2M (+29.4%) | 0.28% -0.017 pp | 0.51% +0.206 pp | USD15.39 +36.5% | 20 qtrs — |
| 60 | CAPITAL FUND MANAGEMENT S.A. | 233.9K -107.3K (-31.5%) | 4.91M -335.6K (-6.4%) | 0.27% -0.125 pp | 0.01% 0.000 pp | USD12.24 +71.7% | 3 qtrs — |
| 61 | CANADA PENSION PLAN INVESTMENT BOARD | 229.6K +— (+0.0%) | 4.82M +1.3M (+36.6%) | 0.27% -0.001 pp | 0.00% +0.001 pp | USD15.39 +36.5% | 2 qtrs — |
| 62 | VIENNA POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. VIENNA INSURANCE GROUP | 200.0K +— (+0.0%) | 4.20M +1.1M (+36.6%) | 0.23% -0.001 pp | 2.05% +0.233 pp | USD12.29 +71.0% | 4 qtrs — |
| 63 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 4.20M +4.2M (+100.0%) | 0.23% +0.231 pp | 0.21% +0.209 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 64 | HENNION & WALSH ASSET MANAGEMENT, INC. | 183.8K +129.1K (+236.0%) | 3.86M +3.0M (+358.9%) | 0.21% +0.149 pp | 0.13% +0.103 pp | USD18.28 +14.9% | 3 qtrs — |
| 65 | HUDSON BAY CAPITAL MANAGEMENT LP | 165.0K -85.0K (-34.0%) | 3.47M -379.6K (-9.9%) | 0.19% -0.099 pp | 0.01% -0.001 pp | USD14.94 +40.6% | 6 qtrs — |
| 66 | JUMP FINANCIAL, LLC | 163.9K +31.2K (+23.5%) | 3.44M +1.4M (+68.7%) | 0.19% +0.036 pp | 0.04% +0.018 pp | USD11.59 +81.3% | 7 qtrs — |
| 67 | RAFFERTY ASSET MANAGEMENT, LLC | 161.9K +20.1K (+14.2%) | 3.40M +1.2M (+55.9%) | 0.19% +0.023 pp | 0.01% +0.005 pp | USD21.60 -2.7% | 22 qtrs — |
| 68 | SWISS NATIONAL BANK | 161.4K +2.9K (+1.8%) | 3.39M +952.5K (+39.1%) | 0.19% +0.003 pp | 0.00% +0.001 pp | USD20.64 +1.8% | 21 qtrs — |
| 69 | WELLS FARGO & COMPANY/MN | 160.9K +103.9K (+182.6%) | 3.38M +2.5M (+285.9%) | 0.19% +0.120 pp | 0.00% +0.000 pp | USD17.86 +17.6% | 38 qtrs — |
| 70 | INVESCO LTD. | 160.5K +27.4K (+20.6%) | 3.37M +1.3M (+64.7%) | 0.19% +0.031 pp | 0.00% +0.000 pp | USD16.73 +25.6% | 24 qtrs — |
| 71 | SEI INVESTMENTS CO | 159.6K +116.2K (+267.4%) | 3.35M +2.7M (+401.8%) | 0.18% +0.134 pp | 0.00% +0.003 pp | USD19.59 +7.2% | 14 qtrs — |
| 72 | Y-INTERCEPT (HONG KONG) LTD | 155.9K +55.1K (+54.6%) | 3.28M +1.7M (+111.1%) | 0.18% +0.063 pp | 0.07% +0.036 pp | USD13.48 +55.9% | 7 qtrs — |
| 73 | UBS ASSET MANAGEMENT AMERICAS INC | 142.4K +8.1K (+6.1%) | 2.99M +926.4K (+44.8%) | 0.16% +0.009 pp | 0.00% +0.000 pp | USD16.63 +26.3% | 21 qtrs — |
| 74 | ATOM INVESTORS LP | 141.7K +141.7K (+100.0%) | 2.98M +3.0M (+100.0%) | 0.16% +0.164 pp | 0.24% +0.236 pp | USD21.01 +0.0% | 5 qtrs — |
| 75 | FMR LLC | 140.6K +135.5K (+2,655.5%) | 2.95M +2.9M (+3,663.1%) | 0.16% +0.156 pp | 0.00% +0.000 pp | USD20.78 +1.1% | 17 qtrs — |
| 76 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 137.6K +137.6K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.16% +0.159 pp | 0.00% +0.005 pp | USD21.01 +0.0% | 11 qtrs — |
| 77 | CITADEL ADVISORS LLC | 137.2K +29.6K (+27.5%) | 2.88M +1.2M (+74.1%) | 0.16% +0.034 pp | 0.00% +0.000 pp | USD15.86 +32.5% | 31 qtrs — |
| 78 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 130.0K +— (+0.0%) | 2.73M +731.3K (+36.6%) | 0.15% -0.001 pp | 1.58% -0.294 pp | USD15.39 +36.5% | 2 qtrs — |
| 79 | SG AMERICAS SECURITIES, LLC | 129.2K +83.8K (+184.5%) | 2.72M +2.0M (+288.4%) | 0.15% +0.097 pp | 0.00% +0.001 pp | USD19.03 +10.4% | 2 qtrs — |
| 80 | PANAGORA ASSET MANAGEMENT INC | 125.1K -30.2K (-19.5%) | 2.63M +238.8K (+10.0%) | 0.14% -0.036 pp | 0.01% 0.000 pp | USD15.39 +36.5% | 2 qtrs — |
| 81 | VOSS CAPITAL, LLC | 125.0K +125.0K (+100.0%) | 2.63M +2.6M (+100.0%) | 0.14% +0.144 pp | 0.13% +0.126 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 82 | RHUMBLINE ADVISERS | 118.8K -12.9K (-9.8%) | 2.50M +470.2K (+23.2%) | 0.14% -0.015 pp | 0.00% +0.000 pp | USD16.96 +23.9% | 31 qtrs — |
| 83 | YELIN LAPIDOT HOLDINGS MANAGEMENT LTD. | 108.4K +— (+0.0%) | 2.28M +609.6K (+36.6%) | 0.13% 0.000 pp | 0.46% +0.106 pp | USD14.52 +44.7% | 10 qtrs — |
| 84 | NEOS INVESTMENT MANAGEMENT LLC | 101.6K -8.5K (-7.7%) | 2.13M +440.3K (+26.0%) | 0.12% -0.010 pp | 0.01% 0.000 pp | USD11.23 +87.1% | 4 qtrs — |
| 85 | TEMA ETFS LLC | 100.1K -10.0K (-9.1%) | 2.10M +408.7K (+24.1%) | 0.12% -0.012 pp | 0.16% +0.023 pp | USD11.23 +87.1% | 4 qtrs — |
| 86 | IEQ CAPITAL, LLC | 99.9K +44.7K (+80.9%) | 2.10M +1.2M (+147.1%) | 0.12% +0.051 pp | 0.01% +0.004 pp | USD17.50 +20.1% | 4 qtrs — |
| 87 | TORRAY INVESTMENT PARTNERS LLC | 97.8K +97.8K (+100.0%) | 2.05M +2.1M (+100.0%) | 0.11% +0.113 pp | 0.29% +0.294 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 88 | ALLIANCEBERNSTEIN L.P. | 94.9K -31.8K (-25.1%) | 1.99M +44.9K (+2.3%) | 0.11% -0.037 pp | 0.00% +0.000 pp | USD16.19 +29.8% | 33 qtrs — |
| 89 | PRICE T ROWE ASSOCIATES INC /MD/ | 94.8K +3.7K (+4.1%) | 1.99M +591.0K (+42.2%) | 0.11% +0.004 pp | 0.00% +0.000 pp | USD18.19 +15.5% | 14 qtrs — |
| 90 | RUSSELL INVESTMENTS GROUP, LTD. | 89.6K +10.1K (+12.7%) | 1.88M +659.6K (+53.9%) | 0.10% +0.011 pp | 0.00% +0.001 pp | USD13.77 +52.6% | 13 qtrs — |
| 91 | TREXQUANT INVESTMENT LP | 87.5K +87.5K (+100.0%) | 1.84M +1.8M (+100.0%) | 0.10% +0.101 pp | 0.02% +0.016 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 92 | LEGAL & GENERAL GROUP PLC | 78.2K -6.3K (-7.5%) | 1.64M +343.0K (+26.4%) | 0.09% -0.008 pp | 0.00% +0.000 pp | USD20.39 +3.0% | 37 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 78.2K -88.0 (-0.1%) | 1.64M +438.5K (+36.4%) | 0.09% 0.000 pp | 0.00% +0.000 pp | USD16.62 +26.4% | 39 qtrs — |
| 94 | STIFEL FINANCIAL CORP | 75.9K -22.4K (-22.8%) | 1.59M +82.0K (+5.4%) | 0.09% -0.026 pp | 0.00% +0.000 pp | USD13.54 +55.2% | 6 qtrs — |
| 95 | DARK FOREST CAPITAL MANAGEMENT LP | 72.7K -87.6K (-54.7%) | 1.53M +26.0K (+1.7%) | 0.08% -0.102 pp | 0.07% +0.025 pp | USD10.08 +108.4% | 4 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
4.00
Bullish
Ratio by volume
3.00
Bullish
Buys
16
Sells
4
Shares acquired
1.20M
Shares disposed
30.1K
Cash buys
—
Cash sales
4.00
Net activity
+1,171,706
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 17,159 | 21.03 | 360.8K | 491,690 | D | ↗ |
| 2026-02-09 | Goldan Keith A. | Officer | S-Sale | D | Common Stock | 3,410 | 21.03 | 71.7K | 140,429 | D | ↗ |
| 2026-02-06 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 7,412 | 20.62 | 152.8K | 508,849 | D | ↗ |
| 2026-02-06 | Goldan Keith A. | Officer | S-Sale | D | Common Stock | 2,082 | 20.62 | 42.9K | 143,839 | D | ↗ |
| 2026-02-04 | Rizo Aleksandra | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 49,000 | D | ↗ |
| 2026-02-04 | Podlesak Dennis | Director | A-Award | A | Common Stock | 48,000 | 0.00 | — | 239,763 | D | ↗ |
| 2026-02-04 | Metzger Michael A | Director / Officer | A-Award | A | Common Stock | 73,000 | 0.00 | — | 371,661 | D | ↗ |
| 2026-02-04 | Legault Pierre | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 114,000 | D | ↗ |
| 2026-02-04 | Katkin Keith | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 124,000 | D | ↗ |
| 2026-02-04 | Jarrett Jennifer | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 114,000 | D | ↗ |
| 2026-02-04 | Huber Martin H. Jr. | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 103,000 | D | ↗ |
| 2026-02-04 | Goldan Keith A. | Officer | A-Award | A | Common Stock | 21,500 | 0.00 | — | 115,171 | D | ↗ |
| 2026-02-04 | Botwood Nicholas A.J. | Officer | A-Award | A | Common Stock | 24,000 | 0.00 | — | 59,165 | D | ↗ |
| 2026-01-30 | Goldan Keith A. | Officer | J-Other | A | Common Stock | 1,219 | 8.48 | 10.3K | 93,671 | D | ↗ |
| 2025-12-01 | Goldan Keith A. | Officer | G-Gift | D | Common Stock | 1,224 | 0.00 | — | 92,452 | D | ↗ |
| 2025-09-08 | Metzger Michael A | Director / Officer | M-Exempt | A | Common Stock | 157,307 | 10.90 | 1.71M | 455,968 | D | ↗ |
| 2025-08-18 | Podlesak Dennis | Director | M-Exempt | D | Stock Options (Right to buy) | 19,200 | 7.20 | 138.2K | 0 | D | ↗ |
| 2025-08-15 | Podlesak Dennis | Director | S-Sale | D | Common Stock | 19,200 | 15.54 | 298.4K | 191,763 | D | ↗ |
| 2025-08-14 | Podlesak Dennis | Director | S-Sale | D | Common Stock | 19,200 | 14.19 | 272.5K | 191,763 | D | ↗ |
| 2025-07-31 | Goldan Keith A. | Officer | J-Other | A | Common Stock | 1,226 | 8.43 | 10.3K | 93,676 | D | ↗ |
| 2025-07-16 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 7,534 | 9.29 | 70.0K | 298,661 | D | ↗ |
| 2025-07-16 | Goldan Keith A. | Officer | S-Sale | D | Common Stock | 1,296 | 9.29 | 12.0K | 92,450 | D | ↗ |
| 2025-05-19 | Katkin Keith | Director | P-Purchase | A | Common Stock | 10,000 | 9.11 | 91.1K | 100,000 | D | ↗ |
| 2025-05-19 | Huber Martin H. Jr. | Director | P-Purchase | A | Common Stock | 5,000 | 8.99 | 45.0K | 79,000 | D | ↗ |
| 2025-05-19 | Goldan Keith A. | Officer | P-Purchase | A | Common Stock | 3,000 | 0.00 | — | 93,746 | D | ↗ |
| 2025-05-16 | Botwood Nicholas A.J. | Officer | P-Purchase | A | Common Stock | 11,765 | 9.00 | 105.8K | 35,165 | D | ↗ |
| 2025-05-12 | Botwood Nicholas A.J. | Officer | — | — | Common Stock | 0 | 0.00 | — | 23,400 | D | ↗ |
| 2025-03-14 | Metzger Michael A | Director / Officer | M-Exempt | A | Common Stock | 6,074 | 7.20 | 43.7K | 306,195 | D | ↗ |
| 2025-03-04 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 7,814 | 15.05 | 117.6K | 300,121 | D | ↗ |
| 2025-02-10 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 13,288 | 15.50 | 206.0K | 300,121 | D | ↗ |
| 2025-02-10 | Goldan Keith A. | Officer | S-Sale | D | Common Stock | 3,777 | 15.50 | 58.6K | 90,746 | D | ↗ |
| 2025-02-10 | Gallagher Neil | Officer | S-Sale | D | Common Stock | 4,618 | 15.50 | 71.6K | 85,095 | D | ↗ |
| 2025-02-05 | Rizo Aleksandra | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-02-05 | Podlesak Dennis | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 191,763 | D | ↗ |
| 2025-02-05 | Meury William | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 90,000 | D | ↗ |
| 2025-02-05 | Metzger Michael A | Director / Officer | A-Award | A | Common Stock | 89,000 | 0.00 | — | 313,409 | D | ↗ |
| 2025-02-05 | Legault Pierre | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 90,000 | D | ↗ |
| 2025-02-05 | Katkin Keith | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 90,000 | D | ↗ |
| 2025-02-05 | Jarrett Jennifer | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 90,000 | D | ↗ |
| 2025-02-05 | Huber Martin H. Jr. | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 74,000 | D | ↗ |
| 2025-02-05 | Goldan Keith A. | Officer | A-Award | A | Common Stock | 18,500 | 0.00 | — | 71,123 | D | ↗ |
| 2025-02-05 | Gallagher Neil | Officer | A-Award | A | Stock Options (Right to buy) | 110,500 | 14.65 | 1.62M | 110,500 | D | ↗ |
| 2024-06-14 | Goldan Keith A. | Officer | P-Purchase | A | Common Stock | 1,250 | 20.03 | 25.0K | 52,623 | — | ↗ |
| 2024-05-15 | Rizo Aleksandra | Director | A-Award | A | Stock Options (Right to buy) | 35,000 | 21.94 | 767.9K | 35,000 | — | ↗ |
| 2024-02-07 | Podlesak Dennis | Director | A-Award | A | Common Stock | 34,000 | 0.00 | — | 141,763 | — | ↗ |
| 2024-02-07 | Morrison Briggs | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 34,836 | — | ↗ |
| 2024-02-07 | Meury William | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 65,000 | — | ↗ |
| 2024-02-07 | Metzger Michael A | Director / Officer | A-Award | A | Common Stock | 107,250 | 0.00 | — | 124,909 | — | ↗ |
| 2024-02-07 | Legault Pierre | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 65,000 | — | ↗ |
| 2024-02-07 | Katkin Keith | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 65,000 | — | ↗ |
| 2024-02-07 | Jarrett Jennifer | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 65,000 | — | ↗ |
| 2024-02-07 | Huber Martin H. Jr. | Director | A-Award | A | Common Stock | 17,000 | 0.00 | — | 49,000 | — | ↗ |
| 2024-02-07 | Goldan Keith A. | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 39,673 | — | ↗ |
| 2024-02-07 | Gallagher Neil | Officer | A-Award | A | Common Stock | 34,688 | 0.00 | — | 34,688 | — | ↗ |
| 2024-01-31 | Goldan Keith A. | Officer | J-Other | A | Common Stock | 1,183 | 17.42 | 20.6K | 4,673 | — | ↗ |
| 2023-08-09 | Morrison Briggs | Director | M-Exempt | A | Common Stock | 52,855 | 8.77 | 463.5K | 70,691 | — | ↗ |
| 2023-08-02 | Meury William | Director | M-Exempt | A | Common Stock | 35,000 | 7.11 | 248.9K | 83,000 | — | ↗ |
| 2023-07-31 | Goldan Keith A. | Officer | J-Other | A | Common Stock | 862 | 18.12 | 15.6K | 3,490 | — | ↗ |
| 2023-07-10 | Morrison Briggs | Director | S-Sale | D | Common Stock | 52,855 | 20.40 | 1.08M | 17,836 | — | ↗ |
| 2023-06-13 | Goldan Keith A. | Officer | S-Sale | D | Common Stock | 577 | 22.31 | 12.9K | 2,628 | — | ↗ |
| 2023-06-09 | Morrison Briggs | Director | M-Exempt | A | Common Stock | 28,273 | 8.77 | 248.0K | 70,691 | — | ↗ |
| 2023-05-09 | Morrison Briggs | Director | M-Exempt | A | Common Stock | 52,855 | 6.38 | 337.2K | 70,691 | — | ↗ |
| 2023-04-10 | Morrison Briggs | Director | M-Exempt | D | Stock Options (Right to buy) | 52,855 | 6.38 | 337.2K | 0 | — | ↗ |
| 2023-04-10 | Gallagher Neil | Officer | A-Award | A | Stock Options (Right to buy) | 250,000 | 19.35 | 4.84M | 250,000 | — | ↗ |
| 2023-03-13 | Morrison Briggs | — | M-Exempt | A | Common Stock | 52,854 | 6.38 | 337.2K | 70,690 | — | ↗ |
| 2023-02-15 | Ordentlich Peter | — | M-Exempt | A | Common Stock | 17,428 | 7.20 | 125.5K | 17,428 | — | ↗ |
| 2023-02-06 | Morrison Briggs | — | S-Sale | D | Common Stock | 52,854 | 26.83 | 1.42M | 17,836 | — | ↗ |
| 2023-02-06 | Metzger Michael A | — | M-Exempt | D | Stock Options (Right to buy) | 5,959 | 6.38 | 38.0K | 0 | — | ↗ |
| 2023-02-02 | Podlesak Dennis | — | A-Award | A | Common Stock | 32,000 | 0.00 | — | 107,763 | — | ↗ |
| 2023-02-02 | Ordentlich Peter | — | A-Award | A | Stock Options (Right to buy) | 90,000 | 28.55 | 2.57M | 90,000 | — | ↗ |
| 2023-02-02 | Nolte Alexander | — | A-Award | A | Stock Options (Right to buy) | 17,000 | 28.55 | 485.4K | 17,000 | — | ↗ |
| 2023-02-02 | Morrison Briggs | — | A-Award | A | Stock Options (Right to buy) | 32,000 | 28.55 | 913.6K | 32,000 | — | ↗ |
| 2023-02-02 | Meury William | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,000 | — | ↗ |
| 2023-02-02 | Metzger Michael A | — | A-Award | A | Stock Options (Right to buy) | 410,000 | 28.55 | 11.71M | 410,000 | — | ↗ |
| 2023-02-02 | Madigan Catherine | — | A-Award | A | Stock Options (Right to buy) | 110,000 | 28.55 | 3.14M | 110,000 | — | ↗ |
| 2023-02-02 | Legault Pierre | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,000 | — | ↗ |
| 2023-02-02 | Katkin Keith | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,000 | — | ↗ |
| 2023-02-02 | Jarrett Jennifer | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,000 | — | ↗ |
| 2023-02-02 | Huber Martin H. Jr. | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2023-02-02 | Goldan Keith A. | — | A-Award | A | Stock Options (Right to buy) | 110,000 | 28.55 | 3.14M | 110,000 | — | ↗ |
| 2023-02-01 | Ordentlich Peter | — | S-Sale | D | Common Stock | 69 | 28.43 | 2.0K | 0 | — | ↗ |
| 2023-01-31 | Ordentlich Peter | — | J-Other | A | Common Stock | 69 | 17.32 | 1.2K | 69 | — | ↗ |
| 2023-01-13 | Legault Pierre | Director | M-Exempt | A | Common Stock | 5,000 | 13.58 | 67.9K | 37,000 | — | ↗ |
| 2023-01-12 | Legault Pierre | Director | M-Exempt | A | Common Stock | 24,000 | 9.47 | 227.3K | 56,000 | — | ↗ |
| 2022-12-05 | Sabus Steve M | Director / Officer | A-Award | A | Stock Options (Right to buy) | 220,000 | 25.44 | 5.60M | 220,000 | — | ↗ |
| 2022-12-02 | Ordentlich Peter | Director / Officer | M-Exempt | A | Common Stock | 17,200 | 6.38 | 109.7K | 17,465 | — | ↗ |
| 2022-12-01 | Ordentlich Peter | Director / Officer | M-Exempt | A | Common Stock | 4,028 | 6.38 | 25.7K | 4,293 | — | ↗ |
| 2022-10-06 | Metzger Michael A | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 16,231 | 0.00 | — | 0 | — | ↗ |
| 2022-10-06 | Katkin Keith | Director | M-Exempt | D | Stock Options (Right to buy) | 20,782 | 0.00 | — | 0 | — | ↗ |
| 2022-10-04 | Metzger Michael A | Director / Officer | M-Exempt | A | Common Stock | 1,280 | 8.77 | 11.2K | 18,939 | — | ↗ |
| 2022-10-04 | Katkin Keith | Director | M-Exempt | A | Common Stock | 137 | 7.88 | 1.1K | 32,137 | — | ↗ |
| 2022-10-03 | Metzger Michael A | Director / Officer | M-Exempt | A | Common Stock | 2,883 | 8.77 | 25.3K | 20,542 | — | ↗ |
| 2022-10-03 | Katkin Keith | Director | M-Exempt | A | Common Stock | 13 | 8.93 | 116.09 | 32,013 | — | ↗ |
| 2022-09-30 | Metzger Michael A | Director / Officer | M-Exempt | A | Common Stock | 29,606 | 8.77 | 259.6K | 47,265 | — | ↗ |
| 2022-09-30 | Katkin Keith | Director | M-Exempt | A | Common Stock | 2,914 | 7.88 | 23.0K | 34,914 | — | ↗ |
| 2022-09-20 | Morrison Briggs | Director / Officer | M-Exempt | A | Common Stock | 59,649 | 10.90 | 650.2K | 77,485 | — | ↗ |
| 2022-09-19 | Morrison Briggs | Director / Officer | M-Exempt | A | Common Stock | 114,339 | 10.90 | 1.25M | 132,175 | — | ↗ |
| 2022-09-16 | Podlesak Dennis | Director | M-Exempt | D | Stock Options (Right to buy) | 5,419 | 6.32 | 34.2K | 0 | — | ↗ |
| 2022-09-16 | Morrison Briggs | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 71,966 | 7.20 | 518.2K | 0 | — | ↗ |
| 2022-09-15 | Podlesak Dennis | Director | M-Exempt | A | Common Stock | 66,840 | 6.32 | 422.4K | 142,603 | — | ↗ |
| 2022-09-15 | Morrison Briggs | Director / Officer | M-Exempt | A | Common Stock | 66,775 | 7.20 | 480.8K | 84,611 | — | ↗ |
| 2022-09-14 | Morrison Briggs | Director / Officer | S-Sale | D | Common Stock | 87,645 | 23.80 | 2.09M | 17,836 | — | ↗ |
| 2022-08-24 | Ordentlich Peter | Officer | M-Exempt | A | Common Stock | 2,154 | 6.35 | 13.7K | 2,419 | — | ↗ |
| 2022-08-05 | Legault Pierre | Director | M-Exempt | A | Common Stock | 14,000 | 8.93 | 125.0K | 46,000 | — | ↗ |
| 2022-07-29 | Ordentlich Peter | Director / Officer | J-Other | A | Common Stock | 265 | 14.12 | 3.7K | 265 | — | ↗ |
| 2022-07-25 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 19,764 | 21.06 | 416.1K | 17,659 | — | ↗ |
| 2022-07-06 | Metzger Michael A | Director / Officer | S-Sale | D | Common Stock | 100 | 21.00 | 2.1K | 17,659 | — | ↗ |
| 2022-07-01 | Morrison Briggs | Director | S-Sale | D | Common Stock | 62,292 | 19.00 | 1.18M | 17,836 | — | ↗ |
| 2022-06-13 | Goldan Keith A. | Director / Officer | A-Award | A | Stock Options (Right to buy) | 230,000 | 15.60 | 3.59M | 230,000 | — | ↗ |
| 2022-04-04 | Morrison Briggs | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 3,128 | 10.90 | 34.1K | 0 | — | ↗ |
| 2022-04-01 | Morrison Briggs | Director | M-Exempt | A | Common Stock | 3,128 | 10.90 | 34.1K | 20,964 | — | ↗ |
| 2022-03-01 | Madigan Catherine | — | A-Award | A | Stock Options (Right to buy) | 180,000 | 16.06 | 2.89M | 180,000 | — | ↗ |
| 2022-02-02 | Podlesak Dennis | — | A-Award | A | Common Stock | 32,000 | 0.00 | — | 75,763 | — | ↗ |
| 2022-02-02 | Ordentlich Peter | — | A-Award | A | Stock Options (Right to buy) | 80,000 | 15.79 | 1.26M | 80,000 | — | ↗ |
| 2022-02-02 | Nolte Alexander | — | A-Award | A | Stock Options (Right to buy) | 30,000 | 15.79 | 473.7K | 30,000 | — | ↗ |
| 2022-02-02 | Morrison Briggs | — | A-Award | A | Stock Options (Right to buy) | 160,000 | 15.79 | 2.53M | 160,000 | — | ↗ |
| 2022-02-02 | Meyers Michael L. | — | A-Award | A | Stock Options (Right to buy) | 17,350 | 15.79 | 274.0K | 17,350 | — | ↗ |
| 2022-02-02 | Meury William | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2022-02-02 | Metzger Michael A | — | A-Award | A | Stock Options (Right to buy) | 325,000 | 15.79 | 5.13M | 325,000 | — | ↗ |
| 2022-02-02 | Legault Pierre | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2022-02-02 | Katkin Keith | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2022-02-02 | Jarrett Jennifer | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2022-02-02 | Huber Martin H. Jr. | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-02-02 | Egros Fabrice | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 32,000 | — | ↗ |
| 2022-02-01 | Ordentlich Peter | — | S-Sale | D | Common Stock | 1,412 | 16.65 | 23.5K | 0 | — | ↗ |
| 2022-02-01 | Nolte Alexander | — | S-Sale | D | Common Stock | 968 | 16.65 | 16.1K | 0 | — | ↗ |
| 2022-01-31 | Ordentlich Peter | — | J-Other | A | Common Stock | 1,412 | 12.39 | 17.5K | 1,412 | — | ↗ |
| 2022-01-31 | Nolte Alexander | — | J-Other | A | Common Stock | 968 | 12.39 | 12.0K | 968 | — | ↗ |
| 2022-01-31 | Meyers Michael L. | — | J-Other | A | Common Stock | 1,714 | 12.39 | 21.2K | 23,280 | — | ↗ |
| 2021-12-30 | Meyers Michael L. | — | M-Exempt | A | Common Stock | 5,900 | 8.77 | 51.7K | 21,566 | — | ↗ |
| 2021-12-22 | Legault Pierre | — | S-Sale | D | Common Stock | 24,000 | 22.01 | 528.2K | 16,000 | — | ↗ |
| 2021-12-20 | Metzger Michael A | — | M-Exempt | A | Common Stock | 45,000 | 8.77 | 394.7K | 62,659 | — | ↗ |
| 2021-12-20 | Legault Pierre | — | M-Exempt | A | Common Stock | 20,000 | 7.08 | 141.6K | 36,000 | — | ↗ |
| 2021-12-17 | Morrison Briggs | Director / Officer | S-Sale | D | Common Stock | 35,156 | 20.00 | 703.1K | 48,336 | — | ↗ |
| 2021-12-17 | Metzger Michael A | — | S-Sale | D | Common Stock | 1,676 | 19.02 | 31.9K | 17,659 | — | ↗ |
| 2021-12-16 | Metzger Michael A | — | M-Exempt | A | Common Stock | 22,715 | 6.38 | 144.9K | 40,374 | — | ↗ |
| 2021-12-13 | Metzger Michael A | — | S-Sale | D | Common Stock | 34,564 | 19.05 | 658.6K | 17,659 | — | ↗ |
| 2021-11-18 | Egros Fabrice | — | S-Sale | D | Common Stock | 30 | 18.03 | 540.97 | 16,000 | — | ↗ |
| 2021-10-26 | Metzger Michael A | — | M-Exempt | A | Common Stock | 16,296 | 7.20 | 117.3K | 33,955 | — | ↗ |
| 2021-10-25 | Metzger Michael A | — | M-Exempt | A | Common Stock | 44,704 | 7.20 | 321.9K | 62,363 | — | ↗ |
| 2021-10-22 | Nolte Alexander | — | — | D | Stock Options (Right to buy) | 35,000 | 19.36 | 677.6K | 0 | — | ↗ |
| 2021-10-05 | Podlesak Dennis | — | J-Other | A | Common Stock | 463 | 0.00 | — | 43,763 | — | ↗ |
| 2021-09-27 | Metzger Michael A | — | M-Exempt | A | Common Stock | 24,437 | 7.20 | 175.9K | 42,096 | — | ↗ |
| 2021-09-22 | Metzger Michael A | — | M-Exempt | D | Stock Options (Right to buy) | 300 | 7.20 | 2.2K | 0 | — | ↗ |
| 2021-09-21 | Metzger Michael A | — | M-Exempt | A | Common Stock | 4,808 | 7.20 | 34.6K | 22,467 | — | ↗ |
| 2021-09-20 | Morrison Briggs | — | M-Exempt | D | Stock Options (Right to buy) | 50 | 7.20 | 360.00 | 0 | — | ↗ |
| 2021-09-20 | Metzger Michael A | — | S-Sale | D | Common Stock | 31,455 | 19.24 | 605.0K | 17,659 | — | ↗ |
| 2021-09-17 | Morrison Briggs | — | M-Exempt | A | Common Stock | 70,262 | 7.20 | 505.9K | 118,598 | — | ↗ |
| 2021-09-15 | Huber Martin H. Jr. | — | A-Award | A | Stock Options (Right to buy) | 35,000 | 19.36 | 677.6K | 35,000 | — | ↗ |
| 2021-09-14 | Metzger Michael A | — | M-Exempt | A | Common Stock | 44,349 | 7.20 | 319.3K | 62,008 | — | ↗ |
| 2021-09-13 | Metzger Michael A | — | S-Sale | D | Common Stock | 16,651 | 19.02 | 316.6K | 17,659 | — | ↗ |
| 2021-08-18 | Egros Fabrice | — | M-Exempt | A | Common Stock | 15,635 | 7.88 | 123.2K | 31,635 | — | ↗ |
| 2021-05-18 | Egros Fabrice | — | S-Sale | D | Common Stock | 1,683 | 18.65 | 31.4K | 16,000 | — | ↗ |
| 2021-04-26 | Meyers Michael L. | Officer | P-Purchase | A | Common Stock | 500 | 15.46 | 7.7K | 15,666 | — | ↗ |
| 2021-04-22 | Podlesak Dennis | — | P-Purchase | A | Common Stock | 13,967 | 14.11 | 197.1K | 43,300 | — | ↗ |
| 2021-03-01 | Egros Fabrice | — | M-Exempt | A | Common Stock | 74 | 7.20 | 532.80 | 26,241 | — | ↗ |
| 2021-02-08 | Morrison Briggs | — | S-Sale | D | Common Stock | 35,156 | 20.55 | 722.4K | 48,336 | — | ↗ |
| 2021-02-03 | Podlesak Dennis | — | A-Award | A | Common Stock | 29,333 | 0.00 | — | 29,333 | — | ↗ |
| 2021-02-03 | Ordentlich Peter | — | A-Award | A | Stock Option (Right to Buy) | 80,000 | 21.36 | 1.71M | 80,000 | — | ↗ |
| 2021-02-03 | Morrison Briggs | — | A-Award | A | Stock Option (Right to Buy) | 195,000 | 21.36 | 4.17M | 195,000 | — | ↗ |
| 2021-02-03 | Meyers Michael L. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 21.36 | 1.71M | 80,000 | — | ↗ |
| 2021-02-03 | Meury William | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2021-02-03 | Metzger Michael A | — | A-Award | A | Stock Option (Right to Buy) | 160,000 | 21.36 | 3.42M | 160,000 | — | ↗ |
| 2021-02-03 | Legault Pierre | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2021-02-03 | Katkin Keith | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2021-02-03 | Karydas Daphne | — | A-Award | A | Stock Option (Right to Buy) | 95,000 | 21.36 | 2.03M | 95,000 | — | ↗ |
| 2021-02-03 | Jarrett Jennifer | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2021-02-03 | Egros Fabrice | — | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2021-02-01 | Metzger Michael A | — | M-Exempt | D | Stock Options (Right to buy) | 15,000 | 7.20 | 108.0K | 0 | — | ↗ |
| 2021-01-31 | Morrison Briggs | — | J-Other | A | Common Stock | 1,771 | 12.00 | 21.3K | 48,336 | — | ↗ |
| 2021-01-31 | Meyers Michael L. | Officer | J-Other | A | Common Stock | 1,771 | 12.00 | 21.3K | 15,166 | — | ↗ |
| 2020-12-01 | Metzger Michael A | — | M-Exempt | A | Common Stock | 15,000 | 7.20 | 108.0K | 32,659 | — | ↗ |
| 2020-11-23 | Ordentlich Peter | — | S-Sale | D | Common Stock | 5,684 | 23.33 | 132.6K | 24,288 | — | ↗ |
| 2020-11-10 | Morrison Briggs | — | M-Exempt | A | Common Stock | 17,466 | 7.20 | 125.8K | 64,031 | — | ↗ |
| 2020-11-09 | Morrison Briggs | — | M-Exempt | A | Common Stock | 62,938 | 7.20 | 453.2K | 109,503 | — | ↗ |
| 2020-11-04 | Metzger Michael A | — | S-Sale | D | Common Stock | 100,000 | 20.31 | 2.03M | 17,659 | — | ↗ |
| 2020-07-31 | Meyers Michael L. | Officer | J-Other | A | Common Stock | 2,665 | 7.97 | 21.2K | 13,395 | — | ↗ |
| 2020-07-13 | Karydas Daphne | — | — | D | Employee Stock Option (right to buy) | 215,000 | 18.95 | 4.07M | 0 | — | ↗ |
| 2020-07-06 | Meyers Michael L. | — | A-Award | A | Common Stock | 3,500 | 0.00 | — | 10,730 | — | ↗ |
| 2020-02-12 | Shea Richard P | — | A-Award | A | Stock Option (Right to Buy) | 43,200 | 9.47 | 409.1K | 43,200 | — | ↗ |
| 2020-02-12 | Podlesak Dennis | — | A-Award | A | Stock Option (Right to Buy) | 44,000 | 9.47 | 416.7K | 44,000 | — | ↗ |
| 2020-02-12 | Ordentlich Peter | — | A-Award | A | Stock Option (Right to Buy) | 50,000 | 9.47 | 473.5K | 50,000 | — | ↗ |
| 2020-02-12 | Morrison Briggs | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 194,000 | 9.47 | 1.84M | 194,000 | — | ↗ |
| 2020-02-12 | Meyers Michael L. | — | A-Award | A | Stock Option (Right to Buy) | 50,825 | 9.47 | 481.3K | 50,825 | — | ↗ |
| 2020-02-12 | Meury William | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 9.47 | 227.3K | 24,000 | — | ↗ |
| 2020-02-12 | Metzger Michael A | — | A-Award | A | Common Stock | 15,000 | 0.00 | — | 17,659 | — | ↗ |
| 2020-02-12 | Legault Pierre | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 9.47 | 227.3K | 24,000 | — | ↗ |
| 2020-02-12 | Katkin Keith | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 9.47 | 227.3K | 24,000 | — | ↗ |
| 2020-02-12 | Jarrett Jennifer | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 9.47 | 227.3K | 24,000 | — | ↗ |
| 2020-02-12 | Egros Fabrice | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 9.47 | 227.3K | 24,000 | — | ↗ |
| 2020-02-04 | Morrison Briggs | — | P-Purchase | A | Common Stock | 12,500 | 8.00 | 100.0K | 43,900 | — | ↗ |
| 2020-01-31 | Shea Richard P | — | J-Other | A | Common Stock | 1,505 | 7.97 | 12.0K | 7,121 | — | ↗ |
| 2019-10-10 | Morrison Briggs | Director / Officer | P-Purchase | A | Common Stock | 11,000 | 5.40 | 59.4K | 31,400 | — | ↗ |
| 2019-07-31 | Shea Richard P | — | J-Other | A | Common Stock | 1,401 | 4.89 | 6.9K | 5,616 | — | ↗ |
| 2019-07-04 | Metzger Michael A | — | A-Award | A | Stock Option (Right to Buy) | 200,000 | 9.15 | 1.83M | 200,000 | — | ↗ |
| 2019-06-10 | Podlesak Dennis | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 7.88 | 346.7K | 44,000 | — | ↗ |
| 2019-06-10 | Meury William | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 7.88 | 189.1K | 24,000 | — | ↗ |
| 2019-06-10 | Legault Pierre | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 7.88 | 189.1K | 24,000 | — | ↗ |
| 2019-06-10 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 7.88 | 189.1K | 24,000 | — | ↗ |
| 2019-06-10 | Jarrett Jennifer | — | A-Award | A | Stock Option (Right to Buy) | 24,000 | 7.88 | 189.1K | 24,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-932.0K
Shares Outstanding
88.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael A. Metzger Chief Executive Officer | 754.3K | — | 2.02M | 3.45M | 848.6K | 10.0K | 7.09M | 77.25% | ↗ |
| 2 | 2025 | Nick Botwood, M.B.B.S. Head of Research & Development, Chief Medical Officer | 345.7K | — | 285.8K | 1.91M | 334.1K | — | 2.88M | 76.39% | ↗ |
| 3 | 2025 | Keith A. Goldan Chief Financial Officer | 516.9K | — | 569.6K | 1.05M | 325.6K | 10.0K | 2.47M | 65.50% | ↗ |
| 4 | 2025 | Luke J. Albrecht General Counsel and Secretary | 496.9K | — | 540.3K | 949.0K | 335.4K | 10.0K | 2.33M | 63.87% | ↗ |
| 5 | 2025 | Steve Closter Chief Commercial Officer | 485.3K | — | 496.4K | 806.7K | 327.6K | 10.0K | 2.13M | 61.29% | ↗ |
| 6 | 2024 | Michael A. Metzger Chief Executive Officer | 715.0K | — | 3.26M | 3.21M | 515.5K | 10.0K | 7.71M | 83.90% | ↗ |
| 7 | 2024 | Steve Closter Chief Commercial Officer | 364.2K | — | 745.3K | 2.22M | 214.8K | 10.0K | 3.56M | 83.44% | ↗ |
| 8 | 2024 | Neil Gallagher, M.D., Ph.D. President, Head of Research & Development | 546.0K | — | 1.07M | 1.04M | 269.6K | 10.0K | 2.93M | 71.80% | ↗ |
| 9 | 2024 | Keith A. Goldan Chief Financial Officer | 497.0K | — | 1.04M | 1.05M | 229.2K | 10.0K | 2.82M | 73.93% | ↗ |
| 10 | 2024 | Luke J. Albrecht General Counsel and Secretary | 471.0K | — | 868.9K | 897.3K | 222.5K | 10.0K | 2.47M | 71.51% | ↗ |
| 11 | 2023 | Michael A. Metzger Chief Executive Officer | 678.4K | — | — | 8.02M | 417.2K | 8.0K | 9.13M | 87.91% | ↗ |
| 12 | 2023 | Neil Gallagher, M.D., Ph.D. President, Head of Research & Development | 386.5K | — | — | 3.32M | 182.2K | 5.3K | 3.89M | 85.25% | ↗ |
| 13 | 2023 | Keith A. Goldan Chief Financial Officer | 470.3K | — | — | 2.15M | 196.4K | 8.0K | 2.83M | 76.13% | ↗ |
| 14 | 2023 | Catherine Madigan, M.D. Chief Medical Officer | 468.6K | — | — | 2.15M | 179.2K | 8.0K | 2.81M | 76.64% | ↗ |
| 15 | 2023 | Luke J. Albrecht General Counsel and Secretary | 442.1K | — | — | 1.96M | 181.3K | 8.0K | 2.59M | 75.62% | ↗ |
| 16 | 2022 | Michael A. Metzger Chief Executive Officer | 640.0K | — | — | 3.06M | 403.2K | 8.0K | 4.11M | 74.44% | ↗ |
| 17 | 2022 | Steve M. Sabus Chief Commercial Officer | 38.0K | — | — | 3.88M | — | — | 3.92M | 99.03% | ↗ |
| 18 | 2022 | Keith A. Goldan Chief Financial Officer | 249.9K | — | 50.0K | 2.50M | 186.8K | 8.0K | 2.99M | 85.14% | ↗ |
| 19 | 2022 | Catherine Madigan, M.D. Chief Medical Officer | 503.5K | — | — | 1.98M | 152.2K | 8.0K | 2.64M | 74.90% | ↗ |
| 20 | 2022 | Briggs W. Morrison, M.D. President, Head of Research and Development and Former Chief Executive Officer | 637.5K | — | — | 1.39M | 334.7K | 8.0K | 2.37M | 58.71% | ↗ |
| 21 | 2022 | Luke J. Albrecht General Counsel and Secretary | 421.0K | — | — | 862.3K | 176.8K | 8.0K | 1.47M | 58.73% | ↗ |
| 22 | 2022 | Alexander Nolte Vice President, Chief Accounting Officer and Former Interim Principal Financial Officer | 338.0K | — | — | 323.4K | 91.5K | 8.0K | 760.9K | 42.50% | ↗ |
| 23 | 2021 | Briggs W. Morrison, M.D. Chief Executive Officer | 618.6K | — | — | 2.97M | 309.3K | 8.0K | 3.90M | 76.03% | ↗ |
| 24 | 2021 | Briggs W. Morrison, M.D. President, Head of Research and Development and Former Chief Executive Officer | 618.6K | — | — | 2.97M | 309.3K | 8.0K | 3.90M | 76.03% | ↗ |
| 25 | 2021 | Michael A. Metzger Chief Executive Officer | 594.1K | — | — | 2.43M | 297.1K | 8.0K | 3.33M | 73.03% | ↗ |
| 26 | 2021 | Michael A. Metzger Chief Operating Officer | 594.1K | — | — | 2.43M | 297.1K | 8.0K | 3.33M | 73.03% | ↗ |
| 27 | 2021 | Daphne Karydas Former Chief Financial Officer | 307.7K | 50.0K | — | 1.78M | 130.8K | 8.0K | 2.28M | 78.21% | ↗ |
| 28 | 2021 | Anjali Ganguli Chief Business Officer | 308.6K | — | 193.6K | 1.43M | 134.0K | 8.0K | 2.07M | 78.23% | ↗ |
| 29 | 2020 | Daphne Karydas Chief Financial Officer | 200.9K | — | — | 2.85M | 80.8K | — | 3.13M | 91.00% | ↗ |
| 30 | 2020 | Daphne Karydas Former Chief Financial Officer | 200.9K | — | — | 2.85M | 80.8K | — | 3.13M | 91.00% | ↗ |
| 31 | 2020 | Briggs W. Morrison, M.D. President, Head of Research and Development and Former Chief Executive Officer | 600.5K | — | — | 1.27M | 285.3K | 6.0K | 2.17M | 58.82% | ↗ |
| 32 | 2020 | Briggs W. Morrison, M.D. Chief Executive Officer | 600.5K | — | — | 1.27M | 285.3K | 6.0K | 2.17M | 58.82% | ↗ |
| 33 | 2020 | Michael A. Metzger Chief Operating Officer | 576.8K | — | 142.1K | 950.7K | 274.0K | 6.0K | 1.95M | 56.05% | ↗ |
| 34 | 2020 | Michael A. Metzger Chief Executive Officer | 576.8K | — | 142.1K | 950.7K | 274.0K | 6.0K | 1.95M | 56.05% | ↗ |
| 35 | 2019 | Michael A. Metzger Chief Operating Officer | 540.3K | — | — | 1.90M | 252.0K | 3.0K | 2.70M | 70.51% | ↗ |
| 36 | 2019 | Briggs W. Morrison, M.D. Chief Executive Officer | 583.1K | — | — | 763.6K | 262.4K | 3.0K | 1.61M | 47.37% | ↗ |
| 37 | 2019 | Michael L. Meyers, M.D., Ph.D. Chief Medical Officer | 424.4K | — | — | 219.2K | 152.8K | 22.2K | 818.5K | 26.78% | ↗ |
| 38 | 2018 | Briggs W. Morrison, M.D. Chief Executive Officer | 566.1K | — | — | 1.26M | 247.7K | 3.0K | 2.08M | 60.74% | ↗ |
| 39 | 2018 | Michael A. Metzger Chief Operating Officer | 506.4K | — | — | 790.5K | 221.5K | 3.0K | 1.52M | 51.96% | ↗ |
| 40 | 2018 | Michael L. Meyers, M.D., Ph.D. Chief Medical Officer | 412.0K | — | — | 474.8K | 144.2K | 20.9K | 1.05M | 45.13% | ↗ |
| 41 | 2017 | Briggs W. Morrison, M.D. Chief Executive Officer | 549.6K | — | — | 920.0K | 204.5K | 3.0K | 1.68M | 54.86% | ↗ |
| 42 | 2017 | Michael A. Metzger Chief Operating Officer | 491.6K | — | — | 546.2K | 182.9K | 3.0K | 1.22M | 44.64% | ↗ |
| 43 | 2017 | Michael L. Meyers, M.D., Ph.D. Chief Medical Officer | 400.0K | — | — | 379.8K | 132.7K | 21.0K | 933.6K | 40.69% | ↗ |
| 44 | 2016 | Briggs W. Morrison, M.D. Chief Executive Officer | 525.4K | 100.0K | — | — | 244.3K | 3.0K | 872.7K | 0.00% | ↗ |
| 45 | 2016 | Michael A. Metzger Chief Operating Officer | 470.4K | 40.0K | — | — | 218.5K | 3.0K | 731.9K | 0.00% | ↗ |
| 46 | 2016 | Michael L. Meyers, M.D., Ph.D. Chief Medical Officer | 378.8K | — | — | — | 152.5K | 19.6K | 550.8K | 0.00% | ↗ |
| 47 | 2015 | Briggs W. Morrison, M.D. Chief Executive Officer | 263.8K | 109.6K | — | 4.26M | 100.2K | — | 4.73M | 89.99% | ↗ |
| 48 | 2015 | Michael A. Metzger Chief Operating Officer | 296.5K | 50.0K | — | 2.55M | 120.0K | 3.0K | 3.02M | 84.45% | ↗ |
| 49 | 2015 | Michael L. Meyers, M.D., Ph.D. Chief Medical Officer | 140.6K | — | — | 1.21M | 43.8K | 4.5K | 1.39M | 86.46% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer & Director | 1M | male |
| Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer | 736.2K | male |
| Luke J. Albrecht | Senior Vice President, General Counsel & Secretary | 703.5K | male |
| Steven Closter | Chief Commercial Officer | 687.3K | male |
| Richard A. Heyman | Co-Founder | — | — |
| Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board | — | — |
| Sharon Klahre | Vice President of Investor Relations & Communications | — | — |
| Michael Downes | Co-Founder | — | — |
| Kevin McManus | Chief People Officer | — | male |
| Joseph Paul Eder | Member of Scientific Advisory Board & Chief Medical Officer | — | — |
| Peter Ordentlich | Co-Founder & Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
